Innovent Biologics Inc. has announced the commencement of the Phase 2 clinical study for efdamrofusp alfa (IBI302), a pioneering anti-VEGF and anti-complement bispecific fusion protein, aimed at treating diabetic macular edema $(DME.AU)$. The study, which marks the first global comparison of two dual-target agents, includes 150 participants divided into three groups to evaluate the efficacy and safety of the drug. Efdamrofusp alfa, developed by Innovent, has shown promising results in earlier trials, offering the potential for improved visual acuity and extended dosing intervals for DME patients. This trial could pave the way for a Phase 3 clinical study and provide a new treatment option for millions affected by DME, particularly in China where the disease is a leading cause of vision impairment among diabetics.